Home Cart Sign in  
Chemical Structure| 1883299-62-4 Chemical Structure| 1883299-62-4

Structure of Brepocitinib
CAS No.: 1883299-62-4

Chemical Structure| 1883299-62-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Brepocitinib is an effective dual inhibitor of JAK1 and TYK2, used to treat various immune-mediated diseases. It selectively inhibits related kinases, blocking inflammatory signaling pathways, with broad clinical application potential.

Synonyms: PF-06700841; PF-841

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Brepocitinib

CAS No. :1883299-62-4
Formula : C18H21F2N7O
M.W : 389.40
SMILES Code : FC1(F)C[C@H]1C(N2C3CCC2CN(C3)C4=NC(NC5=CN(C)N=C5)=NC=C4)=O
Synonyms :
PF-06700841; PF-841
MDL No. :MFCD31813694

Safety of Brepocitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Brepocitinib

epigenetics
RTK
JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HTR-8/SVneo cells 20 nM 24 hours Inhibited the activation of the JAK1/STAT3 pathway and blocked the promoting effects of hyperin on the proliferation, migration, and invasion of HTR-8/SVneo cells Heliyon. 2023 Jan 13;9(1):e12958.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05523765 Non-infectious Intermediate Uv... More >>eitis|Non-infectious Posterior Uveitis|Non-infectious Pan Uveitis Less << PHASE2 COMPLETED 2024-07-30 Clinical Trial Site, Los Angel... More >>es, California, 90095, United States|Clinical Trial Site, Palo Alto, California, 94303, United States|Clinical Trial Site, Pasadena, California, 91107, United States|Clinical Trial Site, Lakewood, Colorado, 80228, United States|Clinical Trial Site, Waltham, Massachusetts, 02451, United States|Clinical Trial Site, Saint Louis, Missouri, 63110, United States|Clinical Trial Site, Palisades Park, New Jersey, 07650, United States|Clinical Trial Site, Durham, North Carolina, 27710, United States|Clinical Trial Site, Winston-Salem, North Carolina, 27157, United States|Clinical Trial Site, Eugene, Oregon, 97401, United States|Clinical Trial Site, Nashville, Tennessee, 37203, United States|Clinical Trial Site, Bellaire, Texas, 77401, United States|Clinical Trial Site, Katy, Texas, 77494, United States|Clinical Trial Site, Plano, Texas, 75075, United States|Clinical Trial Site, Salt Lake City, Utah, 84107, United States Less <<
NCT04260464 Healthy Volunteer|Renal Impair... More >>ment Less << PHASE1 COMPLETED 2022-05-04 Investigational Drug Services ... More >>(IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami, Florida, 33136, United States|University of Miami Division of Clinical Pharmacology, Miami, Florida, 33136, United States|Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, 55114, United States Less <<
NCT06433999 Dermatomyositis|Dermatomyositi... More >>s, Adult Type Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-03-25 Clinical Trial Site, Scottsdal... More >>e, Arizona, 85259, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.84mL

2.57mL

1.28mL

25.68mL

5.14mL

2.57mL

References

 

Historical Records

Categories